导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.33% | 2575/4773 |
| 近一周 | -3.05% | 3586/5462 |
| 近一月 | -10.35% | 5034/5421 |
| 近一季 | 12.52% | 106/5209 |
| 近半年 | 3.50% | 894/4920 |
| 近一年 | -16.60% | 3805/4366 |
| 近两年 | 37.24% | 2006/2954 |
| 近三年 | 1.99% | 1892/2253 |
| 成立以来 | -40.50% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.54% 2351/4961 |
-2.15% 3391/5312 |
- - |
- - |
| 2025 | 19.97% 2161/4813 |
6.15% 671/3635 |
7.15% 403/4076 |
22.75% 1618/4524 |
-14.07% 4331/4813 |
| 2024 | -15.68% 2486/3463 |
-15.79% 2552/2808 |
-11.99% 2579/3014 |
23.75% 370/3129 |
-8.06% 2826/3463 |
| 2023 | -11.17% 1374/2656 |
-1.80% 1892/2280 |
-10.28% 2099/2385 |
3.01% 208/2515 |
-2.13% 430/2655 |
| 2022 | -25.32% 1309/2207 |
-11.25% 490/1919 |
-3.70% 1837/2016 |
-20.77% 1877/2113 |
10.27% 177/2208 |
| 2021 | -9.43% 1077/1822 |
-1.87% 548/1255 |
13.52% 287/1330 |
-11.01% 1250/1466 |
-8.64% 1587/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发中证创新药产业ETF VS. 长安沪深300非周期A(740101) |